Sign in
Stories
DZS Inc. Faces Securities Lawsuit, Nymox CEO Challenged
Share
DZS Inc. Faces Accounting Issues and Cla...
DZS Inc. Faces Multiple Class Action Law...
Investor Alerts: Accounting and Misleadi...
Investor Alert: Alleged Misleading State...
Investor Alert: Lead Plaintiff Deadlines
Investor Alert: Misleading Statements De...
Overview
API
DZS Inc. is facing a securities class action lawsuit alleging false and misleading statements about its financial reporting. Hagens Berman is urging investors to submit their losses and focusing on the propriety of DZS's accounting and internal controls. Nymox CEO is being challenged by a committee to restore shareholder value by publishing the 2022 FDA refusal to file correspondence.
Ask a question
How might the publication of the FDA refusal to file correspondence impact Nymox's shareholder value?
What are the potential consequences for DZS Inc. if found guilty of false accounting?
What measures can companies take to ensure proper accounting and internal controls?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
May 2023
Jun 2023
Jul 2023
Coverage